Discussion on Critical Points for a Tailored Therapy to Cure Hepatitis C Virus Infection

Overview

Journal Clin Mol Hepatol

Specialty Gastroenterology

Date 2019 Jan 24

PMID 30669818

Citations 15

Authors

Nadia Marascio

Angela Quirino

Giorgio Settimo Barreca

Luisa Galati

Chiara Costa

Vincenzo Pisani

Maria Mazzitelli

Giovanni Matera

Maria Carla Liberto

Alfredo Foca

Carlo Torti

Affiliations

Soon will be listed here.

Abstract

Hepatitis C virus (HCV) infects around 71 million people worldwide and in 2018 it is still a major health problem. Since 2011, anti-HCV therapy with availability of direct-acting antiviral drugs has revolutionized the clinical response and paved the way to eradication strategies. However, despite the high rate of sustained virological response, treatment failure may occur in a limited percentage of patients, possibly due to resistance-associated substitutions (RASs), either emergent or pre-existent even in minority viral populations. Clearly this problem may impair success of eradication strategies. With this background, several questions marks still exist around HCV treatment, including whether pan-genotypic treatments with complete effectiveness in any clinical conditions really exist outside clinical trials, the actual cost-effectiveness of genotyping testing, and utility of RAS detection in viral quasispecies by next generation sequencing approach. In this review, we describe these critical points by discussing recent literature data and our research experience.

Citing Articles

Laboratory Biochemical and Hematological Parameters: Early Predictive Biomarkers for Diagnosing Hepatitis C Virus Infection.

Bagheri S, Fard G, Talkhi N, Rashidi Zadeh D, Mobarra N, Mousavinezhad S J Clin Lab Anal. 2024; 38(24):e25127.

PMID: 39569979 PMC: 11659729. DOI: 10.1002/jcla.25127.

Evaluating short-term and long-term liver fibrosis improvement in hepatitis C patients post-DAA treatment.

Wang Y, Ma X, Zou Y, Yue M, Zhang M, Yu R J Biomed Res. 2024; :1-10.

PMID: 38808546 PMC: 11461531. DOI: 10.7555/JBR.37.20230284.

Differences in HCV Seroprevalence, Clinical Features, and Treatment Outcomes between Female and Male Incarcerated Population: Results from a Matched Cohort Study.

Fiore V, De Vito A, Rastrelli E, Manca V, De Matteis G, Ranieri R Viruses. 2023; 15(12).

PMID: 38140655 PMC: 10747283. DOI: 10.3390/v15122414.

Epidemiology and Genotype Distribution of Hepatitis C Virus in Russia.

Pimenov N, Kostyushev D, Komarova S, Fomicheva A, Urtikov A, Belaia O Pathogens. 2022; 11(12).

PMID: 36558817 PMC: 9781887. DOI: 10.3390/pathogens11121482.

The Role of the Microbiota Gut-Liver Axis during HCV Chronic Infection: A Schematic Overview.

Marascio N, De Caro C, Quirino A, Mazzitelli M, Russo E, Torti C J Clin Med. 2022; 11(19).

PMID: 36233804 PMC: 9572099. DOI: 10.3390/jcm11195936.

References

Torti C, Foca A, Carosi G . Towards HCV extinction with modern HCV treatment? "Yes we can!". BMC Infect Dis. 2012; 12 Suppl 2:S1. PMC: 3495622. DOI: 10.1186/1471-2334-12-S2-S1. View

Poordad F, Pol S, Asatryan A, Buti M, Shaw D, Hezode C . Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure. Hepatology. 2017; 67(4):1253-1260. PMC: 5901397. DOI: 10.1002/hep.29671. View

Torti C, Zazzi M, Abenavoli L, Trapasso F, Cesario F, Corigliano D . Future research and collaboration: the "SINERGIE" project on HCV (South Italian Network for Rational Guidelines and International Epidemiology). BMC Infect Dis. 2012; 12 Suppl 2:S9. PMC: 3495626. DOI: 10.1186/1471-2334-12-S2-S9. View

Zeuzem S, Mizokami M, Pianko S, Mangia A, Han K, Martin R . NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome. J Hepatol. 2017; 66(5):910-918. DOI: 10.1016/j.jhep.2017.01.007. View

Pawlotsky J . Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens. Gastroenterology. 2016; 151(1):70-86. DOI: 10.1053/j.gastro.2016.04.003. View

Borgia S, Hedskog C, Parhy B, Hyland R, Stamm L, Brainard D . Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes. J Infect Dis. 2018; 218(11):1722-1729. DOI: 10.1093/infdis/jiy401. View

Bartlett S, Grebely J, Eltahla A, Reeves J, Howe A, Miller V . Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic review. Hepatol Commun. 2018; 1(5):379-390. PMC: 5721421. DOI: 10.1002/hep4.1050. View

Bagaglio S, Uberti-Foppa C, Morsica G . Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use. Drugs. 2017; 77(10):1043-1055. DOI: 10.1007/s40265-017-0753-x. View

Liberto M, Marascio N, Zicca E, Matera G . Epidemiological features and specificities of HCV infection: a hospital-based cohort study in a university medical center of Calabria region. BMC Infect Dis. 2012; 12 Suppl 2:S4. PMC: 3495624. DOI: 10.1186/1471-2334-12-S2-S4. View

10.

Paolucci S, Premoli M, Novati S, Gulminetti R, Maserati R, Barbarini G . Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs. Sci Rep. 2017; 7(1):16017. PMC: 5700050. DOI: 10.1038/s41598-017-15987-1. View

11.

Ito J, Suda G, Yamamoto Y, Nagasaka A, Furuya K, Kumagai K . Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infection. Hepatol Res. 2016; 46(13):1294-1303. DOI: 10.1111/hepr.12685. View

12.

Cuypers L, Ceccherini-Silberstein F, Van Laethem K, Li G, Vandamme A, Rockstroh J . Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time. Rev Med Virol. 2016; 26(6):408-434. DOI: 10.1002/rmv.1895. View

13.

Stelzl E, Appel H, Mehta R, Marins E, Berg J, Paar C . Evaluation of the new cobas® HCV genotyping test based on real-time PCRs of three different HCV genome regions. Clin Chem Lab Med. 2016; 55(4):517-521. DOI: 10.1515/cclm-2016-0620. View

14.

Cho B, Kim S, Song I, Lee S, Kim H, Lee T . Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study. Clin Mol Hepatol. 2017; 23(1):51-56. PMC: 5381834. DOI: 10.3350/cmh.2016.0053. View

15.

European Association For The Study Of The Liver . Corrigendum to 'EASL recommendations on treatment of hepatitis C: Final update of the series [J Hepatol 73 (2020) 1170-1218]. J Hepatol. 2022; 78(2):452. DOI: 10.1016/j.jhep.2022.10.006. View

16.

Younossi Z, Stepanova M, Jacobson I, Asselah T, Gane E, Lawitz E . Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3. Aliment Pharmacol Ther. 2017; 47(2):259-267. DOI: 10.1111/apt.14423. View

17.

Polilli E, Cento V, Restelli U, Ceccherini-Silberstein F, Aragri M, Di Maio V . Consequences of inaccurate hepatitis C virus genotyping on the costs of prescription of direct antiviral agents in an Italian district. Clinicoecon Outcomes Res. 2016; 8:467-473. PMC: 5028103. DOI: 10.2147/CEOR.S106238. View

18.

Chhatwal J, Chen Q, Ayer T, Bethea E, Kanwal F, Kowdley K . Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA. Aliment Pharmacol Ther. 2018; 47(7):1023-1031. PMC: 5842132. DOI: 10.1111/apt.14527. View

19.

Smith D, Bukh J, Kuiken C, Muerhoff A, Rice C, Stapleton J . Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2013; 59(1):318-27. PMC: 4063340. DOI: 10.1002/hep.26744. View

20.

Struble K, Chan-Tack K, Qi K, Naeger L, Birnkrant D . Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation. Hepatology. 2017; 67(2):482-491. DOI: 10.1002/hep.29601. View